Comment
Author: Admin | 2025-04-28
Formulary Chapter 4: Central nervous system - Full Chapter Chapter Links... NICE: Should I stop my benzodiazepine or z-drug? Details... 04.05 Drugs used in the treatment of obesity 04.05.01 Anti-obesity drugs acting on the gastro-intestinal tract Liraglutide (Saxenda®)(Weight loss) Formulary Injection (Saxenda®). Nevolat® and Biolide® are generic versions. NICE TA664 - Liraglutide for managing overweight and obesity.The use of liraglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place. NUH use only:Approved as an adjunct for weight management in paediatric patients over 12 years old. To be prescribed through the NUH paediatric Complications from Excess Weight (CEW) clinic. Link to reviews NICE TA664: Liraglutide for managing overweight and obesity Semaglutide (Wegovy®)(Weight loss) Formulary Injection Oct 23-Work is ongoing locally to plan for the implementation of NICE TA875. Semaglutide for weight loss in adults will only be available to patients that meet the eligibility criteria outlined by NICE and only through a specialist weight management service. See patient information section of the NICE guidance for further details. For use at NUH only: Approved as an adjunct for weight management in paediatric patients over 12 years old. To be prescribed through the NUH paediatric Complications from Excess Weight (CEW) clinic. NICE TA875: Semaglutide to manage overweight & obesity 04.05.02 Centrally acting appetite suppressants .... Non Formulary Items Naltrexone/ bupropion (Mysimba®) Non Formulary Not recommended by NICE in TA494 Link to reviews Risk minimisation materials for Mysimba 8mg/90mg prolonged release tablets Orlistat Non Formulary CapsuleGPs should not prescribe, instead patents should be referred to a Public Health obesity management program in accordance with NICE guidance. Continual monitoring makes it inappropriate for the hospital to initiate.Orlistat - GREY (was AMBER 3), GPs are not commissioned to provide a weight management service. To be reviewed if tier 3 weight management service is commissioned. NICE CG189: Obesity: identification, assessment and management MHRA: Interaction with HIV medicines Nottinghamshire Area Prescribing Committee March 2022 Bulletin Link to reviews Rimonabant (Acomplia®) Non Formulary Marketing authorisation suspended Oct 2008. Link to reviews Setmelanotide (Imcivree®) Non Formulary Solution for InjectionNICE HST21: For treating obesity caused by LEPR or POMC deficiency in people aged 6 years and over. NICE HST31: For treating obesity and hyperphagia in Bardet-Biedl syndrome in people aged 6 years and over.NUH is not a specialist centre, please refer patients to the appropriate specialist centre. Sibutramine Hydrochloride (Reductil®) Non Formulary CapsuleMarketing authorisation suspended Jan 2010 MHRA information on drug withdrawal Key Restricted Drug Unlicensed Link to adult BNF Link to children's BNF Link to SPCs Scottish Medicines Consortium Cytotoxic Drug Controlled Drug High Cost Medicine Cancer Drugs Fund NHS England Homecare ICB Low carbon footprint Medium carbon footprint High carbon footprint Status Description Grey / Non-Formulary: Medicines, which the Nottinghamshire APC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data.Grey / Non-Formulary (undergoing assessment): Work is ongoing and will be reviewed at a
Add Comment